ClinicalTrials.gg
RecruitingNCT06562907Updated Oct 6, 2026

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 1 interventional study of GS-4571 and Placebo in Weight Management, sponsored by Gilead Sciences. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM).

The primary objectives of this study are:

  • To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571.
  • To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571.
  • To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.
02

Conditions studied

  • Weight Management
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 through 55 years, for Parts A, B, and C, and 18 through 65 years, for Part D.
  • Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening.
  • Part A (SAD) and Part B (Food/PPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with of ≥ 19 and \< 30 kg/m\^2, and no significant medical history.

Individuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose.

  • Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg/m\^2 and \< 45 kg/m\^2 with a total body weight > 50 kg, and nondiabetic ( \< 6.5%). Eligible individuals will also be individuals with stable body weight (\< 5% change) for 90 days prior to screening visit based on individual report.
  • Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \< 30 kg/m\^2 and treated with diet and/or exercise, and/or metformin monotherapy.

Key Exclusion Criteria:

  • Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes [with the exception of T2DM for individuals included in Part D only]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or that are or requiring treatment.
  • Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening.
  • Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia).
  • Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator.
  • History of syncope, palpitations, or unexplained dizziness.
  • Active, or history of, significant cardiac disease or conduction abnormality
  • History of implanted defibrillator or pacemaker.
  • Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic , therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).
  • Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Part A Single-ascending Dose (SAD) in Healthy Participants

    Participants will be randomized into 4 + (optional) 1 dose escalating cohorts and will receive GS-4571 or placebo to match (PTM) GS-4571 on Day 1, to determine the maximum tolerated dose: * Cohort 1: Dose 1 GS-4571, administered orally as a single dose, in a fasting state. * Cohort 2: Dose 2 GS-4571, administered orally as a single dose, in a fasting state. * Cohort 3: Dose 3 GS-4571, administered orally as a single dose, in a fasting state. * Cohort 4: Dose 4 GS-4571, administered orally as a single dose, in a fasting state. * Cohort 5 (optional): Dose 5 GS-4571, administered orally as a single dose, in a fasting state.

    Drug: GS-4571 · Drug: Placebo

  • Experimental
    Part B Food/PPI Effect in Healthy Participants

    Participants will be randomized into 2 sequence groups in Cohort 6 and will receive the highest dose found to be safe and well tolerated in Part A of GS-4571 and omeprazole. The two sequential groups will receive the following treatments: * Treatment A: Up to the highest single dose of GS-4571 evaluated in Part A, fasting. * Treatment B: Up to the highest single dose of GS-4571 evaluated in Part A, nonfasting (high-fat/high-calorie meal). * Treatment C (optional): Omeprazole, once-daily (QD) for 5 days, fasting. * Treatment D (optional): Omeprazole followed by up to the highest single dose of GS-4571 evaluated in Part A, 2 hours later, fasting.

    Drug: GS-4571 · Drug: Omeprazole

  • Experimental
    Part C Multiple-ascending Dose (MAD) in Nondiabetic Obese Participants

    Participants randomized in Cohorts 7-9 will be randomized to receive up to 4 escalating doses of GS-4571 or PTM QD for 12 weeks, as follows: * Cohort 7: Up to dose determined from Part A of GS-4571 or PTM in obese participants, QD, in a non-fasting state * Cohort 8: Up to 3-fold the Cohort 7 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state * Cohort 9: Up to 2-fold the Cohort 8 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state * Cohort 10 is optional and will receive GS-4571 or PTM QD for 12 weeks in case it is opened for enrollment as follows: * Up to 2-fold the Cohort 9 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state.

    Drug: GS-4571 · Drug: Placebo

  • Experimental
    Part D Multiple Dose in Nonobese Participants With T2DM

    Participants randomized in Cohort 11 will receive up to the highest dose of GS-4571 or PTM in T2DM, QD, in a non-fasting state for 12 weeks.

    Drug: GS-4571 · Drug: Placebo

Interventions

  • DrugGS-4571

    Administered orally

  • DrugPlacebo

    Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Single-Dose PK Parameter AUCinf of GS-4571

    AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time.

    Time frame: Up to 96 hours postdose

  2. Single-Dose PK Parameter Cmax of GS-4571

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: Up to 96 hours postdose

  3. Multiple-Dose Plasma PK Parameter: AUCtau of GS-4571

    AUCtau is defined as area under the concentration versus time curve over the dosing interval.

    Time frame: Up to 96 hours postdose

  4. Multiple-Dose Plasma PK Parameter: Cmax of GS-4571

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: Up to 96 hours postdose

  5. Percentage of Participants of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Deaths

    Time frame: Day 1 up to 95 days

  6. Percentage of Participants of Treatment-Emergent Laboratory Abnormalities

    Time frame: Day 1 up to 95 days

Secondary outcomes

  1. Percentage Change From Baseline (CFB) in Body Weight in Nondiabetic Obese Participants

    Time frame: Day 1 up to 95 days

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2024 (actual). Primary completion is estimated for Feb 2027, 30 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Nov 2026 → Feb 2027 and completion Nov 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 20, 2024
StartActual
Aug 28, 2024
Primary completionEst.
Feb 2027was Nov 2026
CompletionEst.
Feb 2027was Nov 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Feb 2027
Oct 6, 2026
Study completion
Nov 2026→Feb 2027
Oct 6, 2026
Eligibility
Maximum age 55 Years→65 Years; 1 criterion added
What changed in the criteria
  • AddedAge 18 through 55 years, for Parts A, B, and C, and 18 through 65 years, for Part D.
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Nov 2026→Feb 2027
    Study completion Nov 2026→Feb 2027
    Eligibility Maximum age 55 Years→65 Years; 1 criterion added
    What changed in the criteria
    • AddedAge 18 through 55 years, for Parts A, B, and C, and 18 through 65 years, for Part D.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06562907
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Aug 28, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion